1000577-78-5 Usage
Uses
Used in Organic Synthesis:
Tert-butyl1-benzylazetidin-3-ylcarbamate is used as a building block in organic synthesis for the preparation of more complex and diverse chemical structures. Its unique structure and functional groups allow for various chemical reactions and modifications, facilitating the creation of novel compounds with potential applications in different fields.
Used in Pharmaceutical Development:
In the pharmaceutical industry, tert-butyl1-benzylazetidin-3-ylcarbamate is used as a precursor or intermediate in the synthesis of new drugs and biologically active compounds. Its azetidine ring and carbamate functionality may contribute to the development of compounds with specific therapeutic properties, such as antimicrobial, antiviral, or anticancer agents.
Used in Chemical Research:
Tert-butyl1-benzylazetidin-3-ylcarbamate is utilized in chemical research to study its properties and potential applications. Researchers may investigate its reactivity, stability, and interactions with other molecules to gain insights into its potential uses and limitations. This knowledge can help guide the design and development of new compounds and materials based on the unique characteristics of tert-butyl1-benzylazetidin-3-ylcarbamate.
Check Digit Verification of cas no
The CAS Registry Mumber 1000577-78-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,5,7 and 7 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1000577-78:
(9*1)+(8*0)+(7*0)+(6*0)+(5*5)+(4*7)+(3*7)+(2*7)+(1*8)=105
105 % 10 = 5
So 1000577-78-5 is a valid CAS Registry Number.
1000577-78-5Relevant academic research and scientific papers
PRMT5 INHIBITORS AND USES THEREOF
-
Paragraph 00499, (2016/01/12)
Described herein are compounds of Formula (I)-(XIII), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
